[1] ZHAO YL, HAN S, GUAN XD, et al.The enlightenment of American drug effect evaluation Program to Chinese drug evaluation system[J].Chinese Journal of Pharmacy(中国药学杂志), 2015, 50(13): 1156-1159. [2] National Health Commission. Notice of National Health Commission on Drug Use Monitoring and Clinical Comprehensive Evaluation[EB/OL]. (2014-09-02)[2022-04-19].http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=31149bb1845e4c019a04f30c0d69c2c9. [3] National Health Commission.Next year, the scope of drug use monitoring will basically cover public medical institutions at level two and above[J]. Modern Health(现代养生), 2019(8): 2. [4] Members of the Project Team. Reference outline of guidelines for comprehensive evaluation of Chinese drugs[J]. Drug Evaluation(药品评价), 2015, 12(8):26. [5] CHEN Y, CHI X, HE Y, et al.Mapping of health technology assessment in China: situation analysis and international comparison[J]. Int J Technol Assess Health Care, 2019, 35(5): 401-407. [6] MCDONAGH MS, JONAS DE, GARTLEHNER G, et al.Methods for the drug effectiveness review project[J]. BMC Medical Research Methodology, 2012, 12(1): 140. [7] VANLARE JM, WONG HH, GIBBS J, et al.Comparative effectiveness research in practice: the drug effectiveness review project experience[J]. J Comp Eff Res, 2013, 2(6): 541-550. [8] AHRQ Publication.Methods guide for effectiveness and comparative effectiveness reviews[M]. MD:AHRQ, 2014. [9] BIRCH S, GAFNI A.On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales[J]. Health Econ, 2002, 11(3): 185-191. [10] ZHENG YM, WU J.Hate or use? A brief look at the application status of UK health technology assessment[J]. Chinese Pharmacoeconomics(中国药物经济学), 2010, 5(2): 77-86. [11] HILL SR.Zaheer-Ud-Din babar(ed): pharmaceutical prices in the 21st century[J]. Pharmacoeconomics, 2015, 34(3): 1-2. [12] National Institute for Health and Care Excellence. Guide to the Processes of Technology Appraisal[EB/OL]. (2014-09-02)[2022-04-19]. https://pubmed.ncbi.nlm.nih.gov/27905710/. [13] YUE XF, ZHANG F, LIU YH, et al.Decision-making transformation mechanism and enlightenment of NICE health technology assessment process in UK[J]. Chinese Health Economics(中国卫生经济), 2021, 40(1): 91-96. [14] BATTISTA RN, FEENY DH, HODGE MJ.Evaluation of the Canadian coordinating office for health technology assessment[J]. Int J Technol Assess Health Care, 1995, 11(1): 102-116. [15] WU CH.Status of health technology assessment in Canada[J]. Chinese Medicine Biotechnology(中国医药生物技术), 2007, 2(2): 157-158. [16] Australian Government Department of Health. Therapeutic goods administration australian register of therapeutic goods[EB/OL]. (2019-10-29)[2022-04-19]. https://www.tga.gov.au/australian-register-therapeutic-goods. [17] Australian Government Department of Health. TGA and PBAC parallel process and requirements[EB/OL]. (2021-09-22)[2022-04-19]. https://www.pbs.gov.au/info/publication/factsheets/shared/tga-pbac-parallel-process. [18] ZHU Y, JIANG R, SHAO R.Research on parallel procedures of drug registration and medical insurance access in Australia[J]. China Health Economy, 2018, 37(11): 89-92. [19] LIU GN, HU SL, WU JH. China pharmacoeconomic evaluation guide (2011 Edition)[J]. Chinese Pharmacoeconomics(中国药物经济学), 2011(3): 6-9, 11-48. [20] SUN X, TAN J, TANG L, et al.A technical framework system for post-marketing drug evaluation based on real-world evidence: reflections and suggestions[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2018, 18(4): 277-283. [21] ZHANG ZZ, CHEN C, LIU X, et al.Investigation on the application status of health technology assessment in my country[J]. Medical Information(医学信息), 2019, 32(23): 22-25. [22] TANG JB.Significance and method of clinical drug evaluation[J]. Chinese Pharmacy(中国药房), 1996, 7(6): 243-246. [23] HUANG SP.Significance and methods of clinical drug evaluation[J]. Journal of Pediatric Pharmacy(儿科药学杂志), 2000, 6(1): 8-9. [24] SHANG PH, LIU J, LIU JT, et al.Research on the comprehensive evaluation index system of drug safety in China[J]. China Health Policy Research(中国卫生政策研究), 2013, 6(10): 41-47. [25] WEI FF, FENG XC, ZHONG L, et al.Construction of drug safety index based on multi-index comprehensive evaluation method[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(9): 545-550. [26] GUO Q.New metrics for drug evaluation[J]. China Pharmaceutical Affairs(中国药事), 1997, 11(5): 72. [27] China Pharmacoeconomic Evaluation Guidelines research group. China pharmacoeconomic evaluation guidelines (2011 edition)[J]. China Journal of Pharmaceutical Economics(中国药物经济学), 2011 (3):7-48. [28] GAO HL, LU Y, JIANG TT, et al.Guidelines for quality assessment of pharmacoeconomic evaluation reports[J]. Chinese Pharmacoeconomics(中国药物经济学), 2019, 14(2): 18-28. [29] LIU BL.Consideration of key technical points in clinical trials of new traditional Chinese medicines for the treatment of stroke[J]. Chinese Journal of New Drugs(中国新药杂志), 2015, 24(10): 1105-1107, 1127. [30] LIU BL.Efficacy evaluation indicators and common evaluation methods in drug clinical trials[J]. Chinese Journal of New Drugs(中国新药杂志), 2016, 25(18):2074-2077. [31] LIU BL.Selection of curative effect indicators in drug clinical trials[J]. Chinese Journal of New Drugs(中国新药杂志), 2017, 26(18): 2113-2120. [32] ZHANG HH, WNAG JF, FAN H,et al.Comprehensive evaluation of daptomycin based on Reference Outline of the Guidelines for Comprehensive Evaluation of Drugs in China-Evaluation of Pharmacological Properties in Vivo[J]. Drug Evaluation(药品评价), 2016, 13(8): 8-12, 59. [33] WANG JF, FAN H, MA K.Evaluation of the effectiveness of daptomycin based on Reference Outline of the Guidelines for Comprehensive Evaluation of Drugs in China[J].Drug Evaluation(药品评价), 2016, 13(6): 19-23,36. [34] WANG JF, FAN H, MA K.Comprehensive evaluation of daptomycin--safety evaluation based on reference outline of the guidelines for comprehensive evaluation of drugs in China[J]. Drug Evaluation(药品评价), 2015, 12(18): 12-18,32. [35] XU XW, LIU RJ, MEI D, et al.Comprehensive evaluation of rebif(recombinant interferon β1a) according to reference outline of the guidelines for comprehensive evaluation of drugs in China[J]. Chinese Journal of Pharmacy(中国药学杂志), 2015, 50(12): 1070-1074. [36] ZHAO ZG, DONG ZJ, LIU JP.Quick guide for drug evaluation and selection in Chinese medical institutions[J]. Medicine Herald(医药导报), 2020, 39(11): 1457-1465. [37] KONG FX, MA AX, LI HC, et al.Definition, measurement and evaluation of comprehensive clinical value of drugs in the perspective of public decision-making[J]. Chinese Pharmacy(中国药房), 2020, 31(5): 539-544. [38] Department of Drug Policy and Essential Drug System, National Health Commission. Announcement on Public Solicitation of Opinions on Management Guidelines for Comprehensive Clinical Evaluation of Drugs[EB/OL]. (2020-11-04)[2022-04-19]. http://www.nhc.gov.cn/yaozs/s7656/202011/d11ddc32fae84121a0dfca36b015a31d.shtml. [39] XIAO Y, NI X, ZHAO K, et al.Research on method guidefor pediatric drug evaluation[J].Chinese Journal of Drug Evaluation(中国药物评价), 2021, 38(6): 479-483. [40] The National Center for Comprehensive Evaluation of Drug and Health Technology. Technical Guidelines for Comprehensive Clinical Evaluation of Antitumor Drugs (2021 Edition)[EB/OL]. (2021-12-31)[2022-01-19].http:/www.nhei.cn/nhei/znfb/202112/9e350a54d2ea4c3ab9a0237ee4eab9f0.shtml. [41] The Health Development Research Center of the National Health Commission.Technical guidelines for clinical comprehensive evaluation of cardiovascular disease drugs:2021 edition[EB/OL].(2021-12-31)[2022-03-22].http://www.nhei.cn/nhei/znfb/202112/9e350-a54d2ea4c3ab9a0237ee4eab9f0/files/0ac56e4cd1e848da-859d623212dd0171.pdf. [42] LIU F, ZHAI SD.Reference outline of guidelines for comprehensive evaluation of drugs in China (second edition) chapter C guidelines for evaluation of drug effectiveness[J]. Drug Evaluation(药品评价), 2015, 12(8): 8-11. [43] WU JH.Reference outline of guidelines for comprehensive evaluation of drugs in china (second edition) chapter vi guidelines for economic evaluation of clinical drugs[J]. Drug Evaluation(药品评价), 2015, 12(8): 16-19. [44] SUN CH.Reference Outline of Guidelines for Comprehensive Evaluation of Drugs in China (Second Edition) ChapterⅤ Guidelines for Evaluation of Drug Compliance[J]. Drug Evaluation(药品评价), 2015, 12(8): 15-16. [45] ZHANG YF, WANG SW, FAN GR.Comprehensive clinical evaluation of nivolumab and pembrolizumab[J]. South-Central Pharmacy(中南药学), 2019, 17(8): 1274-1279. [46] DENG T, WANG Y, HUANG D, et al.Clinical practice guideline development method-GRADE method theory[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine(中国循证心血管医学杂志), 2018, 10(12): 1441-1445, 1449. [47] SHI NN.Research on the formulation procedure of TCM clinical practice guidelines based on comprehensive methods[D]. Beijing: China Academy of Chinese Medical Sciences, 2016. [48] HE W.Concept analysis and type introduction of post-marketing evaluation of drugs in China[J]. South-Central Pharmacy(中南药学), 2015, 13(7): 780-782. [49] BAN YQ, XIA XD, YUAN XL, et al.A brief analysis of the research status of post-marketing drug evaluation in China[C]. Proceedings of the 2013 Annual Meeting of the Pharmacy Management Professional Committee of the Chinese Pharmaceutical Association and the Academic Forum on “Medical Safety and Scientific Development”(Volume 2), 2013: 143-147. [50] SHAN SS, WANG QW, WEN JG.Basic concepts and development norms of clinical guidelines and expert consensus[J]. Chinese Journal of Pediatric Surgery(中华小儿外科杂志), 2020, 41(2): 107-111. [51] CHEN M, QIN K, SHEN J, et al.Application of delphi method to evaluate the index system of nutritional support pharmaceutical care mode[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2020, 40(22): 2366-2371. [52] YANG P, LU S, DONG XZ, et al.Research progress on comprehensive evaluation methods of drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(7): 803-806. [53] JANKNEGT R, VAN DER KUY A, DECLERCK G, et al. Drug selection by means of the system of objectified judgement analysis (SOJA) method[J]. Pharmacoeconomics, 1996, 10(2): 152-63. [54] JANKNEGT R.Triptans in the treatment of migraine: drug selection by means of the SOJA method[J]. Expert Opin Pharmacother, 2007, 8(Suppl1): S15-30. [55] XIE TT, GUO DH.Drug evaluation research and progress[J]. Drug Application and Monitoring in China(中国药物应用与监测), 2019, 16(4): 191-195. [56] WEI XD.“Interventions”in pilot studies[J]. Journal of Clinical Pediatric Surgery(临床小儿外科杂志), 2019, 18(7): 547. [57] DHILLON JK, GILL NC.Deciphering the system of a systematic review[J]. Dent Res J (Isfahan), 2014, 11(5): 531-536. [58] HARRIS JD, QUATMAN CE, MANRING MM, et al.How to write a systematic review[J]. Am J Sports Med, 2014, 42(11): 2761-2768. [59] TIAN L, GUAN X, MA AX.Systematic comparison of randomized controlled trial studies and observational studies[J]. Chinese Pharmacy(中国药房), 2018, 29(4): 493-496. [60] ZHANG XB, GUAN HJ, LIU GE.Pharmacoeconomic evaluation of recombinant human interferon uman interferon recombinant human interferon apillomavirus infection[J]. Chinese Pharmacoeconomics(中国药物经济学), 2019, 14(10): 28-37. [61] JIN YH, WU SW, BAI ZG, et al.The connotation and value of systematic evaluation and meta-analysis[J]. Journal of Tongji University (Medical Edition)(同济大学学报医学版), 2019, 40(1): 105-111. [62] DELGADO-RODRIGUEZ M, SILLERO-ARENAS M.Systematic review and meta-analysis[J]. Med Intensiva (Engl Ed), 2018, 42(7): 444-453. [63] SUN X, TAN J, TANG L, et al.Real world evidence: experience and lessons from China[J]. BMJ, 2018, 360(feb059): j5262. [64] BOULKEDID R, ABDOUL H, LOUSTAU M, et al.Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review[J]. PLoS One, 2011, 6(6): e20476. [65] ZHANG LJ, ZHANG XQ.Peer review quality control mechanism and enlightenment of foreign scientific research funding institutions[J]. Technological Progress and Countermeasures(科技进步与对策), 2017, 34(11): 114-117. [66] GUO ZJ, YANG AH.The Development characteristics and experience enlightenment of national science foundation[J]. Research on Dialectics of Nature(自然辩证法研究), 2019, 35(12): 63-68. [67] XU XW.Reference outline of guidelines for comprehensive evaluation of drugs in China-chapter Ⅰ guidelines for drug safety evaluation[J]. Drug Evaluation(药品评价), 2015, 12(8): 7. |